Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for the treatment of bladder disorders

A composition and drug technology, which can be used in drug combinations, sexual diseases, urinary system diseases, etc., and can solve problems such as deterioration and serious bladder inflammation.

Inactive Publication Date: 2012-09-12
RICHTER GEDEON NYRT
View PDF8 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Inflammation in the bladder may become more severe and symptoms may worsen without adequate treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for the treatment of bladder disorders
  • Pharmaceutical composition for the treatment of bladder disorders
  • Pharmaceutical composition for the treatment of bladder disorders

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] Weigh 0.20 mg of sodium hyaluronate (Reag.Ph.Eur.) in a 100 ml flask, then add 5.0 ml of distilled distilled water (water for injection, pyrogen-free, sterile) at a concentration of 0.10 mol / l Zinc solution, followed by double distilled water to bring the volume up to 50 ml. 23.5 ml of a 1.00 mol / l sorbitol solution (prepared with double distilled water) were added. Then, the volume was brought up to 100 ml with double distilled water. Finally, the solution was filtered with a membrane filter.

[0045] animal model test

[0046] Two series of trials were designed to evaluate the efficacy of a zinc hyaluronate solution in regeneration of the bladder wall. In the first series of trials, the experimental pathological process served as a model for the changes that occur in the bladder wall in interstitial cystitis. The second series of tests simulates the acute inflammatory process of the bladder.

Embodiment 2

[0048] Interstitial cystitis model

[0049] The test was done with 20 white female rats. Simulates an experimental pathological process similar to that occurring on the bladder wall in interstitial cystitis. Cryodestruction of the bladder. A cotton swab impregnated with liquid nitrogen is introduced into the bladder and left for 20 seconds to induce interstitial cystitis. Animals were then selected into 3 experimental groups, respectively.

[0050] Test Group 1: 48 hours after freezing impairment, the rats received only one treatment, 1 ml of zinc hyaluronate solution (according to Example 1) was introduced into the bladder of the rats and left for 30 minutes.

[0051] Test Group 2: Animals received the same treatment as Group 1 animals, but 3 times (done in 3 consecutive days).

[0052] Experimental Group 3: 3 control animals received no treatment after freezing impairment.

[0053] Subsequently, the rats were sacrificed with an overdose of sodium thiopental and the blad...

Embodiment 3

[0057] Acute Bacterial Cystitis Model

[0058] The test was done with 16 white female rats. Acute inflammation of the bladder was injected (under pressure) with 1.0ml Escherichia coli culture solution (the concentration of bacteria solution was 10 6 CFU / ml) to induce.

[0059] Animals were then selected into 3 experimental groups:

[0060] Test Group 1: 48 hours after the injection of the E. coli culture solution, the rats received only one treatment, 1 ml of zinc hyaluronate solution (according to Example 1) was introduced into the bladder of the rats and kept for 30 minutes.

[0061] Test Group 2: Rats received the same treatment as Group 1 animals, but 3 times (done in 3 consecutive days).

[0062] Test group 3: 3 control animals received no treatment after injection of E. coli culture solution.

[0063] Subsequently, three groups of rats were sacrificed by overdose of thiopental and their bladders were excised. For histological studies, the above bladder samples were ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to View More

Abstract

The invention relates to pharmaceutical compositions with activity against disorders of urogenital system of mammals which comprises a zinc-hyaluronan complex as active ingredient and a pharmaceutically acceptable carrier and / or additive. The process for the preparation of said pharmaceutical compositions as well as the therapeutic use thereof for the treatment and prevention of diseases associated with abnormalities and deficiencies of glucosaminoglycan (GAG) layer in the urogenital system in mammals and a kit comprising zinc hyaluronate solution, a catheter which is applicable to intravesical administration and optionally a balloon which is applicable to bladder dillatation are also within the scope of the invention.

Description

technical field [0001] The present invention relates to a pharmaceutical composition with activity against mammalian genitourinary system diseases. The pharmaceutical composition contains zinc hyaluronate complex as an active ingredient and pharmaceutically acceptable carriers and / or additives. The preparation method of the pharmaceutical composition, and its therapeutic use for the treatment and prevention of diseases related to abnormalities and defects of the glycosaminoglycan (GAG) layer of the genitourinary system in mammals, and zinc hyaluronate Kits of solutions, catheters usable for intravesical administration, and optionally balloons usable for bladder dilation are also within the scope of the present invention. Background technique [0002] The above-mentioned hyaluronic acid (HA) is a glucosaminoglycan-type homopolymer composed of repeating disaccharide units of N-acetylglucosamine-glucuronic acid of formula (I). [0003] [0004] In hyaluronic acid, the monos...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/728A61K33/30
CPCA61K31/728A61K33/30A61P13/00A61P13/10A61P15/00A61K2300/00
Inventor S·洛瓦茨B·弗尔卡A·泽克利G·弗莱M·罗丹内尤哈茨L·森伊
Owner RICHTER GEDEON NYRT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com